Kornimate/medical-research-clean huggingface dataset:
tracer-guided surgery for recurrent prostate cancer

Conditions: Prostate Cancer

Summary: adt with or without robot-assisted psma-radioguided surgery for patients with recurrent prostate cancer.

improving the oncological treatment outcomes in men with a biochemical recurrence after primary prostate cancer (pc) treatment that are diagnosed with a disease recurrence confined to the regional lymph nodes or local residual disease using prostate specific membrane antigen (psma) positron emission tomography and computed tomography (pet/ct.) the proposed trial randomizes patients with recurrent pc following primary pc treatment to either 6 months of adt or technetium-psma-radioguided salvage surgery plus 6 months of adt. although the optimal duration of adt is unknown, a minimal duration of 6 months of adt seems advisable in this setting and will be mandatory for both arms.

Eligibility criteria:
inclusion criteria: * male, aged ≥ 18 years. * hormone-sensitive recurrent prostate cancer after radical prostatectomy, external beam radiotherapy or brachytherapy * ≤ 2 lymph node metastases or local residual disease within the pelvis with sufficient psma expression (≥2 times regional vascular activity level) as determined by psma-based pet * psa-value \< 4 ng/ml in case of a local recurrence and psa \< 3 ng/ml in case of (a) nodal recurrence(s) * had a psma pet/ct within 90 days before surgery * suitable for salvage surgery, as per institutional guidelines. * charlson comorbidity index ≤ 4 * world health organisation (who) performance status 0, 1, or 2. * written and signed informed consent. exclusion criteria: * other diagnosis of malignancy or evidence of other malignancy within 5 years before screening for this study (except non-melanoma skin cancer). * more than 2 lymph node metastases on psma pet/ct * suspicion of local recurrent prostate cancer within the prostatic fossa not treatable by surgery * non-regional lymphadenopathy (cm1a) or distant metastases (cm1b/c) as assessed by preoperative psma pet/ct. * castration resistance defined by clinical or biochemical progression despite a combined androgen blockade * known contraindications to hormone therapy, according to standard recommendations in force * patient with a psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow-up schedule * ongoing androgen deprivation therapy (adt) or within 6 months prior to surgery. * severe claustrophobia interfering with pet/ct scanning. * absence or withdrawal of an informed consent

Keywords: psma-radioguided surgery adt recurrent prostate cancer
retrograde intrarenal surgery low risk trial

Conditions: Retrograde Intrarenal Surgery; Renal Stones

Summary: in the treatment of kidney stones and upper ureteral stones, flexible ureteroscopic lithotripsy has become the mainstream choice due to its minimally invasive nature and high safety. however, there is still no universal consensus on the use of prophylactic antibiotics before surgery. taiwan, located in the subtropical region, is one of the areas in the world with a high incidence of urinary tract stones. currently, there are no established guidelines for the use of prophylactic antibiotics before flexible ureteroscopic lithotripsy in taiwan. this study aims to evaluate the differences between single-dose, different types of prophylactic antibiotics in generally healthy adult patients undergoing flexible ureteroscopic lithotripsy.

this study focuses on flexible ureteroscopic lithotripsy, a procedure commonly used to treat kidney stones and stones in the upper part of the ureter. this surgery is popular because it is minimally invasive and considered very safe. however, there is no clear agreement on whether or which antibiotics should be given to patients before the surgery to prevent infections. taiwan is one of the regions in the world with a high rate of urinary tract stones, and because of this, it is especially important to ensure that the best practices are followed to prevent infections during and after the surgery. currently, there are no official guidelines in taiwan on which antibiotics should be used before flexible ureteroscopic lithotripsy. this study aims to compare different types of single-dose antibiotics given before the surgery to see if one is more effective than others in preventing infections. by looking at how different antibiotics perform, the study hopes to provide clearer guidance for doctors in choosing the best antibiotic treatment for patients, ultimately improving patient care and reducing the risk of infections after surgery.

Eligibility criteria:
inclusion criteria: * stone diameter \< 3 cm or stone area \< 900 mm2 * preoperative(2 weeks) negative urine culture * no active symptoms , including fever, dysuria, urinary frequency, urgency) * urinalysis wbc \< 10/hpf exclusion criteria: * immunocompromised * poor control diabetes mellitus * allergy to antibiotics * ureteric stents or foley catheter present * ureteric stricture * renal or urethral deformity * antibiotic treatment for urinary tract infection in the preceding 4 weeks

Keywords: retrograde intrarenal surgery prophylactic antibiotics
three dimensional movement analysis of maxillary impacted canine: a randomized clincial trial

Conditions: Complicated Impacted Tooth

Summary: maxillary canines are the second-most frequently impacted teeth in the dental arch after the third molars. the suspicion of a maxilary canine impaction raises with the absence of the permanent canine in the arch after the normal period of eruption, and has to be confirmed by a clinical evaluation of the patient and a radiographic assessment. the approaches to the management of impacted canines are many, but the preferred approach typically involves surgical exposure and guided orthodontic eruption. the initial mechanical eruption can be achieved in several ways, but an important distinction has to be done according to the anchorage method. the aim of this study is comparing temporary anchorage devices (tads), and cantilevers with a tma sectional, using the quantification of canines and molars displacement as the main parameter. a tad is a mini screw temporarily fixed to bone for the purpose of enhancing orthodontic anchorage either by supporting the reactive unit (the anchoring tooth) or by obviating the need for it at large, and is subsequently removed after use. the mini screw employed in this clinical trial will be an alloy type iv titanium screw with 1.5mm diameter and 8-10 mm long, and under local anesthesia will be placed in an area between the first premolar and first molar, on the buccal or labial side according to the canine position and teeth position. for the evaluation of the canines and molar displacement, two cbct will be required: the first one before the beginning of the traction (t0), the second one after three months (t1). both the cbct will be imported in the mimics image processing software (materialize group, leuven, belgium). limiting the tissue density ranges and restricting the anatomical area of interest, a cropped colored mask will be obtained from each cbct. then the co-registration, through the identification of 5 at least landmark points, will allow the overlap of the two masks. at this point, calculating the 3d surface models, the tooth pre- and post-treatment positions will be evident and the measurement of the displacement possible.


Eligibility criteria:
inclusion criteria: * presence of one or two impacted maxillary canine requiring surgical exposure and orthodontic treatment exclusion criteria: * permanent teeth extraction-based treatment * current or previous orthodontic treatment in the last 12 months * current systemic disease * current antibiotic or antinflammatory therapy that can may compromise the result

Keywords: impacted canine miniscrew cone beam
comparison of prohance® with gadovist®/gadavist™ in magnetic resonance imaging (mri) of the brain

Conditions: Brain Disease

Summary: this study aims at a direct comparison between prohance (0.1 mmol/kg) and a validated comparator gadovist/gadavist (0.1 mmol/kg) in a crossover intra-individual design in subjects with brain tumors to confirm the identical overall technical and diagnostic performance of the two mr contrast agents.

adult patients were given two mri exams, one after injection of prohance (0.1 mmol/kg) and one after injection of gadovist/gadavist (0.1 mmol/kg). the exams were performed with identical equipment and imaging parameters with the order of the two exams randomized and 2-14 days between the first and the second mri exam. image data was evaluated by 3 expert neuroradiologist blinded to the agent administered and patient clinical data.

Eligibility criteria:
inclusion criteria: * are scheduled to undergo mri * are willing to undergo two mri procedures within 14 days * have confirmed or are highly suspected of brain disease likely to enhance as determined by the following: * clinical/neurological symptomatology; * diagnostic testing, such as ct or previous mri examinations; or * have had previous brain surgery and are to be evaluated for recurrence. exclusion criteria: * are pregnant or lactating females. exclude the possibility of pregnancy: * by testing on site at the institution within 24 hours prior to the start of each investigational product administration; or * by history (i.e., tubal ligation or hysterectomy); or * post menopausal with a minimum of 1 year without menses * have any known allergy to one or more of the ingredients in the investigational products, or have a history of hypersensitivity to any metals * have congestive heart failure (class iv according to the classification of the new york heart association; see appendix a) * have suffered a stroke within a year * have received or are scheduled to receive any other contrast medium in the 24 hours preceding through the 24 hours following exam 1, and in the 24 hours preceding through the 24 hours following exam 2 * have received or are scheduled to receive an investigational compound and/or medical device within 30 days before admission into the present study, through the 24 hours post-administration of the second investigational product. * have moderate-to-severe renal impairment, defined as a gfr/egfr \< 45 ml/min. * have been previously entered into this study * have received or are scheduled for one of the following: * surgery within three weeks prior to the first examination or between the two examinations * initiation of steroid therapy between the two examinations * radiosurgery between the two examinations * have any contraindications to mri such as a pace-maker, magnetic material (i.e., surgical clips) or any other conditions that would preclude proximity to a strong magnetic field. * are suffering from severe claustrophobia

Keywords: have confirmed or are highly suspected of brain disease
a comparative clinical research on single roux-en-y and traditional roux-en-y of pancreaticojejunostomy-choledochojejunostomy for treatment of obstruction of pancreatic duct and bile duct

Conditions: Pancreatic Cancer

Summary: this study is being done to learn more about how different surgery procedures bring back the quality of life.after removing the small intestine at least 20cm in patients with pancreatic cancer, some patients develop problems because they are disorder their digestive system, such as cramping, heartburn,vomiting.


Eligibility criteria:
inclusion criteria: * patient 30 years of age or older * pathologically confirmed pancreatic cancer (biopsy may be performed at our institution) * no evidence of metastases(a) * decide performe roux-en-y(b) * single roux-en-y reconstruction is technically feasible(c) * patients will be registered and consent obtained, if the surgeon believes there is no evidence of metastases. if metastatic disease is identified at the time of operation, the patient will not be randomized. * patients will be conditionally enrolled, and consent obtained, if the surgeon believes the patient may need a sngle roux-en-y at the time of operation. if a sngle roux-en-y is not performed, the patient will not be randomized. * the surgeon feels that the single roux-en-y is not technically feasible at the time of operation,the patients will be excluded. this may be due to prior abdominal surgery, anatomic variants, or anything else at the surgeon's discretion. exclusion criteria: * not expected to be able to provide follow-up over 2 years (due to geographic or other limitations)

Keywords: single roux-y of pancreaticojejunostomy-choledochojejunostomy
avelumab in previously untreated patients with epithelial ovarian cancer (javelin ovarian 100)

Conditions: Ovarian Cancer

Summary: this is a phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. eligible patients must have previously untreated, histologically confirmed stage iii-iv epithelial ovarian (eoc), fallopian tube cancer (ftc), or primary peritoneal cancer (ppc) and be candidates for platinum-based chemotherapy. the primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.


Eligibility criteria:
key inclusion criteria: * histologically confirmed stage iii-iv epithelial ovarian, fallopian tube, or primary peritoneal cancer, including malignant mixed müllerian tumors with high grade serous component * patients must be candidates for platinum based chemotherapy and previously untreated * patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy * availability of an archival formalin fixed, paraffin embedded (ffpe) tumor tissue block or a minimum of 15 slides * ecog ps 0-1 * adequate hematological, renal, and liver function key exclusion criteria: * non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors * prior systemic anti-cancer treatment for eoc, ftc, or ppc including prior immunotherapy with il 2, ifn α, or anti pd 1, anti pd l1, anti pd l2, anti cd137, or anti cytotoxic t lymphocyte associated antigen 4 (anti ctla 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting t cell co stimulation or immune checkpoint pathways * patients for whom, in the opinion of the investigator, there is clinical benefit to administer bevacizumab as a first-line treatment and for whom bevacizumab is approved and available in this setting. * cancer for which intraperitoneal cytotoxic chemotherapy is planned * active autoimmune disease (some exceptions include diabetes type i, vitiligo, psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)

Keywords: untreated epithelial ovarian fallopian tube primary peritoneal cancer
a clinical study of mr13a9 in hemodialysis patients with pruritus.

Conditions: Uremic Pruritus

Summary: double-blind, placebo-controlled study to evaluate the dose-response relationship of safety, efficacy and pharmacokinetics of ma13a9 in hemodialysis patients with pruritus.


Eligibility criteria:
inclusion criteria: * japanese with male or female aged ≥ 20 * patient with chronic kidney disease (ckd) has been on hemodialysis 3 times per week * patient receiving treatment for itch * patient has a baseline nrs score \> 4 exclusion criteria: * patient has pruritus cause other than ckd or its complications * patients has hepatic cirrhosis * patient has a known history of allergic reaction to opiates
efficacy of classification based 'cognitive functional therapy' in patients with non specific chronic low back pain

Conditions: Chronic Low Back Pain

Summary: a randomized controlled trial of the efficacy of classification based cognitive functional physiotherapy according to the system proposed by peter o'sullivan as compared to manual therapy and exercise in patients with non specific chronic low back pain. the investigators hypothesis was that treatment targeted at the mechanism behind the problem from a multidimensional perspective would be superior to traditional treatment.

nsclbp is widely viewed as a multifactorial biopsychosocial pain syndrome. it has been proposed by several authors that nsclbp represents a vicious cycle associated with different combinations of maladaptive; cognitive (negative beliefs, fear avoidance behaviours, catastrophising, depression, stress, lack of pacing and coping), physical (pain provocative postures, movement patterns and pain behaviours) and lifestyle (inactivity, rest) behaviours that act to promote pain and disability. however a recent systematic review suggests that this change in paradigm and our new understanding of nsclbp has not resulted in clinical trials utilizing multidimensional classification systems or targeted interventions based on the underlying mechanisms. line with this shift in paradigm a novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation of. with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.

Eligibility criteria:
inclusion criteria: * all patients with non-specific lbp for more that 8 weeks duration * mechanical provocation of pain with postures, movement and activities * localised pain in the area from t12 to gluteal folds * moderate ongoing lbp with a vas \> 2/10 * disability had to be higher than 14% on oswestry disability index exclusion criteria: * sick listed for more than 4 months continuous duration * acute exacerbation of lbp * radicular pain with positive neural tissue provocation test * any low limb surgery on the last 3 months * surgery involving the lumbar spine (fusion) * pregnancy * psychiatric disorders - somatisation * dominant psycho-social problems * widespread non-specific pain disorder (no primary lbp focus) * specific diagnoses: active rheumatologic disease, progressive neurological disease, serious cardiac or other internal medical condition, malignant basic diseases, acute traumas, infections, or acute vascular catastrophies

Keywords: cognitive functional therapy manual therapy and exercise chronic low back pain randomized controlled trial subclassification
mobile technology for blood pressure management

Conditions: Hypertension

Summary: the primary objective of this study is to assess the feasibility and effectiveness of a mobile-technology based system that integrates patient-facing and clinician-facing components to assist the management of hypertension.


Eligibility criteria:
inclusion criteria: * 18 years or older with an established diagnosis of essential hypertension exclusion criteria: * patients on more than 2 antihypertensives at time of enrollment * clinical diagnosis of secondary hypertension, that is, hypertension due to a secondary cause, including but not limited to the following: * renal artery stenosis * primary hyperaldosteronism * cushing syndrome * coarctation of the aorta * drug-induced hypertension * pheochromocytoma * obstructive sleep apnea * hospitalization for malignant hypertension or severe hypertension (including stroke, cardiac events, acute kidney injury) in the preceding 6 months * hospitalization for unstable angina or myocardial infarction in the preceding 6 months * prior diagnosis of heart failure or cardiomyopathy * stroke or transient ischemic attack within prior 6 months * prior organ transplantation * failure to obtain informed consent * pregnant or currently trying to become pregnant * patients who are enrolled in other research studies
molecular and cellular characterization of skull base tumors

Conditions: Skull Base Neoplasm; Cellular Pathology

Summary: the purpose of the study is to analyze biological samples and genetic material for basic science research investigating the molecular and cellular characterization of skull base tumors.

the overall goal of this proposal is to determine new molecular and cellular features that define tumor subtypes that are clinically actionable, may drive important changes in patient management, and/or elucidate novel chemotherapeutic options. skull base tumors are currently diagnosed based on histopathologic criteria, on which post-operative management is based. however, the investigators hypothesize that each tumor type (eg. chordoma or chondrosarcoma) will have molecular and/or cellular subcategories that will redefine how to categorize and diagnose patients, predict clinical outcome, and optimally design a patient-specific management strategy. in addition, we aim to catalogue changes that occur after treatment after surgical resection, chemotherapy, and/or radiation by comparing primary and recurrent tumors.

Eligibility criteria:
inclusion criteria: * diagnosis of a skull base tumor exclusion criteria: * insufficient tumor sample at time of resection
hidden impairments during subarachnoid haemorrhage recovery, description and evolution of a newly described syndrom

Conditions: Intracranial Hemorrhages

Summary: descriptive observational study in patients with spontaneous subarachnoid hemorrhage or following aneurysmal rupture to assess the presence of a post-hsa syndrome at 3 months, 6 months and 1 year, and its impact on functional outcome using the rivermead questionnaire

every year, subarachnoid hemorrhage affects 9.1 people per 100,000 worldwide, with a peak between the ages of 50 and 60. its frequency and relatively young age of onset make it a major source of decline in healthy life years. progress over the past thirty years has led to a 57% reduction in mortality, but these figures do not always reflect the day-to-day reality of these patients, for whom recovery remains incomplete in almost half of cases. for example, a third of patients have not returned to work at one year, and of those who have, only half have returned to work full-time. in 2020, a norwegian team showed that, at one year, a third of patients suffer from a "post-hsa syndrome", as yet little described, but which seems very similar to the post-concussion syndrome experienced by patients after head trauma. in their study, only 3% of patients with this syndrome returned to work at one year. a better understanding of the incidence of this syndrome, as well as its evolution and determinants, is therefore essential. with this in mind, the investigators chose to assess the presence of post-sah syndrome at 3 months and its repercussions on return to work, using the rivermead questionnaire. secondly, in view of the prevalence of post-traumatic stress syndrome at 3 years (a quarter of patients), the investigators wished to study the factors determining the presence of post-hsa syndrome and an inability to return to work at 3 months, 6 months, 1 year.

Eligibility criteria:
inclusion criteria: patient aged 18 to 65 * patient hospitalized in intensive care unit at hôpital lariboisière between september 2022 and september 2023 for subarachnoid hemorrhage due to aneurysmal rupture. * patient affiliated to the french social security system * patient expressing no objection exclusion criteria: * motor deficits persisting 1 month after sah * hospitalization \> 1 month * patient does not speak french * patient with diagnosis of neurodegenerative disease. * traumatic meningeal hemorrhage * patients on ame

Keywords: post-hsa syndrome subarachnoid hemorrhage